X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES FRESENIUS KABI ONCO. ALKEM LABORATORIES/
FRESENIUS KABI ONCO.
 
P/E (TTM) x - 22.1 - View Chart
P/BV x 6.3 3.1 202.2% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ALKEM LABORATORIES   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
FRESENIUS KABI ONCO.
Mar-13
ALKEM LABORATORIES/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,589176 902.8%   
Low Rs1,23279 1,569.4%   
Sales per share (Unadj.) Rs417.537.7 1,107.7%  
Earnings per share (Unadj.) Rs56.35.1 1,105.3%  
Cash flow per share (Unadj.) Rs64.76.7 962.5%  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.942.5 688.5%  
Shares outstanding (eoy) m119.57158.23 75.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.4 100.1%   
Avg P/E ratio x25.125.0 100.3%  
P/CF ratio (eoy) x21.818.9 115.2%  
Price / Book Value ratio x4.83.0 161.0%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,65320,135 837.6%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m9,171703 1,304.2%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m49,9155,963 837.1%  
Other income Rs m1,64518 9,139.4%   
Total revenues Rs m51,5615,981 862.1%   
Gross profit Rs m8,4821,430 593.1%  
Depreciation Rs m1,006258 390.0%   
Interest Rs m671-26 -2,579.2%   
Profit before tax Rs m8,4511,216 694.9%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,606342 469.3%   
Profit after tax Rs m6,731806 835.2%  
Gross profit margin %17.024.0 70.9%  
Effective tax rate %19.028.1 67.5%   
Net profit margin %13.513.5 99.8%  
BALANCE SHEET DATA
Current assets Rs m27,0625,102 530.5%   
Current liabilities Rs m15,3242,385 642.4%   
Net working cap to sales %23.545.6 51.6%  
Current ratio x1.82.1 82.6%  
Inventory Days Days67150 44.3%  
Debtors Days Days41113 36.4%  
Net fixed assets Rs m12,6105,148 244.9%   
Share capital Rs m239158 151.1%   
"Free" reserves Rs m34,4906,556 526.1%   
Net worth Rs m35,0276,732 520.3%   
Long term debt Rs m1,212952 127.2%   
Total assets Rs m54,38710,388 523.6%  
Interest coverage x13.6-45.8 -29.7%   
Debt to equity ratio x00.1 24.5%  
Sales to assets ratio x0.90.6 159.9%   
Return on assets %13.67.5 181.3%  
Return on equity %19.212.0 160.5%  
Return on capital %24.914.6 170.2%  
Exports to sales %12.974.5 17.4%   
Imports to sales %3.124.8 12.5%   
Exports (fob) Rs m6,4614,441 145.5%   
Imports (cif) Rs m1,5401,477 104.3%   
Fx inflow Rs m6,5635,298 123.9%   
Fx outflow Rs m3,0121,772 169.9%   
Net fx Rs m3,5523,525 100.7%   
CASH FLOW
From Operations Rs m7,2591,274 569.7%  
From Investments Rs m1,864-1,204 -154.8%  
From Financial Activity Rs m-9,273-196 4,728.6%  
Net Cashflow Rs m-150-126 118.8%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 33.1 0.3 11,033.3%  
FIIs % 0.0 9.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 9.1 -  
Shareholders   68,381 42,599 160.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   BIOCON LTD  CADILA HEALTHCARE  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

US-China Trade Talks, Oil Prices, and Top Stocks in Action Today(Pre-Open)

On Tuesday, share markets in India witnessed selling pressure during closing hours and ended their trading session marginally lower after a volatile day of trading.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 19, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS